high rate of success.to focus on closing sales .Multiple!$$
Added Mr. MacNaught “Over the next month we will continue
to focus on closing sales for VMS+3.2, preparing for the AEPC conference in May, submitting VMS+4.0 to FDA for 510(k) clearance and optimizing our internal processes to support growth. During this time, I will be devoting more time and attention to the U.S. market to ensure that Ventripoint achieves a high rate of success.”